China NT Pharma Group Company Limited (1011.HK)
HKD 0.41
(-7.87%)
HKD 0.41
(-7.87%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.36 Million CNY | -96.44% |
| 2022 | 207.09 Million CNY | -8.65% |
| 2021 | 226.69 Million CNY | 2.24% |
| 2020 | 221.73 Million CNY | -39.41% |
| 2019 | 365.96 Million CNY | -35.97% |
| 2018 | 571.52 Million CNY | -5.51% |
| 2017 | 604.84 Million CNY | -33.91% |
| 2016 | 915.11 Million CNY | 7.95% |
| 2015 | 847.72 Million CNY | -1.95% |
| 2014 | 864.62 Million CNY | 14.65% |
| 2013 | 754.11 Million CNY | 2.03% |
| 2012 | 739.13 Million CNY | -73.2% |
| 2011 | 2.75 Billion CNY | 3.38% |
| 2010 | 2.66 Billion CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 31.29 Million CNY | 0.0% |
| 2023 Q2 | 7.36 Million CNY | 0.0% |
| 2023 FY | 7.36 Million CNY | -96.44% |
| 2022 Q4 | 86.59 Million CNY | 0.0% |
| 2022 Q2 | 120.5 Million CNY | 0.0% |
| 2022 FY | 207.09 Million CNY | -8.65% |
| 2021 FY | 226.69 Million CNY | 2.24% |
| 2021 Q4 | 115.46 Million CNY | 0.0% |
| 2021 Q2 | 111.23 Million CNY | 0.0% |
| 2020 Q2 | 89.43 Million CNY | 0.0% |
| 2020 FY | 221.73 Million CNY | -39.41% |
| 2019 FY | 365.96 Million CNY | -35.97% |
| 2019 Q2 | 94.02 Million CNY | 0.0% |
| 2018 FY | 571.52 Million CNY | -5.51% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q2 | 311.98 Million CNY | 0.0% |
| 2017 Q2 | 314.39 Million CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | 604.84 Million CNY | -33.91% |
| 2016 Q2 | 385.78 Million CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | 915.11 Million CNY | 7.95% |
| 2015 FY | 847.72 Million CNY | -1.95% |
| 2015 Q2 | 380.9 Million CNY | 0.0% |
| 2015 Q4 | 466.82 Million CNY | 0.0% |
| 2014 Q4 | 456.52 Million CNY | 0.0% |
| 2014 FY | 864.62 Million CNY | 14.65% |
| 2014 Q2 | 408.09 Million CNY | 0.0% |
| 2013 Q4 | 227.85 Million CNY | 0.0% |
| 2013 FY | 754.11 Million CNY | 2.03% |
| 2013 Q2 | 526.26 Million CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 FY | 739.13 Million CNY | -73.2% |
| 2012 Q4 | - CNY | 0.0% |
| 2011 FY | 2.75 Billion CNY | 3.38% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 FY | 2.66 Billion CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | 97.158% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 99.93% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | 87.536% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | 99.06% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | 99.234% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 99.3% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 99.568% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | 99.09% |
| PuraPharm Corporation Limited | 406.85 Million HKD | 98.19% |
| SSY Group Limited | 6.46 Billion HKD | 99.886% |
| JBM (Healthcare) Limited | 648.41 Million HKD | 98.864% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 99.498% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.997% |